Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Reports Positive Results from Phase III Lung Cancer Trial of Immunotherapy

publication date: Aug 7, 2020

CStone Pharma announced CS1001, an anti-PD-L1 mAb, met its primary progression-free survival endpoint at an interim analysis in a China Phase III trial. CS1001 was tested as a first-line treatment of stage IV squamous and non-squamous NSCLC. It was administered in combination with platinum-based chemotherapy and compared to platinum chemotherapy alone The median PFS was 7.8 months in the CS1001 cohort compared to 4.9 months in the control group. Based on the trial, the company plans to file an NDA in China soon. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.